Dr. Aaron Shady, Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1601 Creekside Loop, Yakima, WA 98902 Phone: 509-575-1000 Fax: 509-225-2703 |
Dr. Robert P Schefter Jr., MD Otolaryngology Medicare: Medicare Enrolled Practice Location: 1601 Creekside Loop, Yakima Ear Nose And Throat, Yakima, WA 98902 Phone: 509-575-1000 Fax: 509-225-2703 |
Mr. Rick D Gross, MD Otolaryngology - Otolaryngology/Facial Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1601 Creekside Loop, Yakima Ear Nose And Throat, Yakima, WA 98902 Phone: 509-575-1000 Fax: 509-225-2703 |
Bichngoc Thi Nguyen, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1601 Creekside Loop, Yakima, WA 98902 Phone: 509-575-1000 Fax: 509-225-2703 |
Brandon G. Bentz, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1601 Creekside Loop, Yakima, WA 98902 Phone: 509-575-1000 Fax: 509-225-2703 |
Dr. See Young Chris Yang, M.D. Otolaryngology - Otolaryngology/Facial Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 311 S 72nd Ave, Yakima, WA 98908 Phone: 509-972-2028 Fax: 509-972-7842 |
Palmer P Wright, D.O. Otolaryngology - Otolaryngology/Facial Plastic Surgery Medicare: Medicare Enrolled Practice Location: 1601 Creekside Loop, Yakima, WA 98902 Phone: 509-575-1000 Fax: 509-575-0333 |
Dr. Andrew Allan Davenport, D.O. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1601 Creekside Loop, Yakima, WA 98902 Phone: 509-575-1000 Fax: 509-225-2703 |
News Archive
The study, conducted Dr. Kathryn M. Magruder and colleagues, showed that the clinics examined recognized less than half (46.5 percent) the PTSD cases identified by the researchers.
A UCLA-led has study found that after leaving the hospital, nearly two-thirds of Medicare beneficiaries hospitalized for acute ischemic stroke either died or were rehospitalized within a year.
NPS Pharmaceuticals, Inc. today announced the closing of a public offering of 7,912,000 shares of its common stock, including 1,032,000 shares sold pursuant to the full exercise of an overallotment option previously granted to the underwriters. Net proceeds were approximately $44.4 million after deducting underwriting discounts and estimated offering expenses. Jefferies & Company, Inc. acted as the sole book-running manager and Canaccord Genuity Inc. acted as co-lead manager for the offering.
Even with the advent of vaccines, strategies for rapid and affordable testing for COVID-19 are still paramount.
Patients with type 2 diabetes show a progressive decline in glycemic control and receive antidiabetic therapy in order to reach the target glycated hemoglobin level of < 7% set by the American Diabetes Association and the European Association for the Study of Diabetes. An article published in the May 2010 issue of Postgraduate Medicine reviews the effectiveness of oral antidiabetes (OAD) agents in maintaining glycemic control in patients with type 2 diabetes.
› Verified 9 days ago